Home
About +
Our Story
Meet the Team
FAQs
Our Science +
Inhaled IFN-β
Clinical Trials
Publications
Factsheets
Investors +
Investor Overview
Investor News
Reports & Presentations
Major Shareholders & Advisers
Shareholder Information
TR-1/Options Press Release Archive
Careers
Contact
Home
About
Our Science
Investors
Careers
Contact
Back
Our Story
Meet the Team
FAQs
Back
Inhaled IFN-β
Clinical Trials
Publications
Factsheets
Back
Investor Overview
Investor News
Reports & Presentations
Major Shareholders & Advisers
Shareholder Information
TR-1/Options Press Release Archive
Synairgen and Clinigen sign Managed Access Program agreement with SNG001 for treatment of hospitalised patients with COVID-19